Browse our products ranging within diabetes, obesity, haemophilia, human growth hormone and hormone replacement therapy.
Since providing the world’s first injection system more than 90 years ago, we have been committed to making drug delivery as simple and convenient as possible. On this page you will find the instructions for use (IFU) for our durable pens and devices in your language. Our full range may not be available in your country. Please ask your doctor or nurse if you have any questions.
This page is using European product trade names with accompanying generic names. Trade and generic names may differ in other markets.
Links to more details on the European Medicines Agency's (EMA) webpage are provided for those products that have been granted a central marketing authorisation by the European Commission.
* in the US approved under the brand name Xultophy® 100/3.6.
** in the US called NovoLog®
*** in the US spelt Novoeight®
**** in the US approved under the name of REBINYN®
1 approved in the US and received positive opinion in EU